Stockscreener 앱 받기
18.54
3.46%
0.62
시장 영업 전:
18.45
-0.09
-0.49%
전일 마감가:
$17.92
열려 있는:
$17.92
하루 거래량:
784.98K
Relative Volume:
1.49
시가총액:
$1.02B
수익:
-
순이익/손실:
$-121.52M
주가수익비율:
-8.3154
EPS:
-2.2296
순현금흐름:
$-113.06M
1주 성능:
+5.88%
1개월 성능:
+13.26%
6개월 성능:
+53.73%
1년 성능:
+35.63%
1일 변동 폭
$16.93
$18.77
1주일 범위
$16.12
$18.77
52주 변동 폭
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.54 | 981.69M | 0 | -121.52M | -113.06M | -2.2296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
BCAX (Nasdaq) insider sale: 16,300 shares via option exercise (03/04/2026) - Stock Titan
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug - simplywall.st
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Bicara hire gets 115,000 stock options as job inducement - Stock Titan
BCAX (NASDAQ) insider to sell 13,555 shares after option exercise - Stock Titan
Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX) - Stock Titan
BCAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Bicara Therapeutics Inc benefit from rate cuts2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Major Insider Move Signals Growing Confidence in Bicara Therapeutics - TipRanks
Bicara Therapeutics (BCAX) stake reaches 11.5% at RA Capital group - Stock Titan
RA Capital funds boost Bicara Therapeutics (BCAX) stake with stock and warrants - Stock Titan
Assessing Bicara Therapeutics (BCAX) Valuation After Recent Share Price Moves And DCF Implied Upside - simplywall.st
Bicara Therapeutics (BCAX) President/COO sells 3,631 shares after option exercise - Stock Titan
Bicara Therapeutics closes $172.5 million stock offering By Investing.com - Investing.com India
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Bicara Therapeutics Strengthens Finances with Equity Offering - TipRanks
Bicara Therapeutics Inc. closes oversubscribed equity offering to fund ficerafusp alfa advancement - Traders Union
Bicara Therapeutics closes $172.5 million stock offering - Investing.com South Africa
Bicara Therapeutics (NASDAQ: BCAX) raises $161.8M to fund ficerafusp alfa - Stock Titan
Bicara raises $172.5M to back planned ficerafusp alfa U.S. launch - Stock Titan
Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX - Defense World
BCAX Should I Buy - Intellectia AI
Bicara Therapeutics prices $150 million stock offering at $16 By Investing.com - Investing.com Australia
Ryan Cohlhepp sells BCAX shares (BCAX) in multiple transactions - Stock Titan
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:BCAX) 2026-02-25 - Seeking Alpha
Bicara Therapeutics Announces Public Offering Details - Intellectia AI
Biotech prices $150M deal to fund solid tumor drug plans in US - Stock Titan
Bicara Therapeutics Prices $150 Million Securities Offering - marketscreener.com
Bicara Therapeutics (NASDAQ: BCAX) raises up to $172M via share and warrant sale - Stock Titan
Bicara Therapeutics Prices Public Offering at $16.00 per Share - Intellectia AI
Bicara Therapeutics prices $150 million stock offering at $16 - Investing.com
Bicara Therapeutics says co. prices public offering of 7,175,000 shares at $16.00 each - marketscreener.com
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Bicara Therapeutics Says Co. Prices Public Offering Of 7,175,000 Shares At $16.00 Each - TradingView
Bicara Therapeutics launches $150 million stock offering By Investing.com - Investing.com Australia
Bicara Therapeutics launches $150 million stock offering - Investing.com
Bicara Therapeutics announces proposed public offering of common stock - marketscreener.com
Bicara Therapeutics Announces Proposed Public Offering of Common Stock - TradingView
Cancer drug push: Bicara seeks $150M stock sale for launch prep - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap UpShould You Buy? - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Bicara Therapeutics stock rating reaffirmed by Citizens at Market Outperform - Investing.com UK
Bicara Therapeutics Shares New FICERA Data, Eyes Less Frequent Dosing in Head & Neck Cancer - MarketBeat
Biotech firm Bicara heads to Boston and Miami for investor talks - Stock Titan
Bicara Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Bicara Therapeutics Inc. (BCAX): Investor Outlook Reveals an 89.84% Potential Upside in Biotech Market - DirectorsTalk Interviews
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):